Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth
Abstract
Objective To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).Method Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.Results At study entry, children were taller and heavier than average. Growth delays were largest for weight and BMI, and there was a 13 percentile point decrease in height. Children continued to grow in terms of height while treated with LDX; we found no increase in raw weight or BMI during the study period. LDX treatment was significantly associated with diminished gains in height, weight, and BMI compared to levels that would be expected based on age-appropriate standards from the Centers for Disease Control. Growth delays were greatest for the heaviest and tallest children, for those who had not previously received stimulant therapy, and for those with a greater cumulative exposure to LDX. More work is needed to determine effects on ultimate adult height.Conclusions Consistent with prior studies of stimulants, treatment with LDX leads to statistically significant reductions in expected height, weight, and BMI. Growth of patients with ADHD treated with LDX should be closely monitored and corrective action taken should growth delays be observed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a 15-month follow-up of 282 children treated with lisdexamfetamine, Faraone et al showed slowing of growth in weight, height, and body mass index compared with Centers for Disease Control norms.
“In a 15-month follow-up of 282 children treated with lisdexamfetamine, Faraone et al25 used weight, height, and body mass index to show that there was slowing of growth on all the above parameters when compared with Centers for Disease Control norms.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [25]
This growth delay was associated with the children being stimulant-naïve, heavier and taller on entry into the study, and having greater cumulative exposure to medication.
“This delay was associated with the children being stimulant-naïve, heavier and taller on entry into the study, and having “greater cumulative exposure” to medication.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [25]
The efficacy and side-effects of LDX are similar to the other long-acting stimulant preparations.
“The efficacy and side-effects of LDX are similar to the other long-acting stimulant preparations [68-72].”
From Advances in understanding and treating ADHD (2011) · cites this paper as [71]
Cites
CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000
Kuczmarski, R. J., Ogden, C. L., Guo, S. S., Strawn, L. G., Flegal, K. M., & Mei, Z. (2002) · Cited by 6,426 · see citing works
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404 · see citing works
MTA Cooperative Group (2004) · PEDIATRICS · doi:10.1542/peds.113.4.762 · Cited by 384 · see citing works
Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 356 · see citing works
Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up
SWANSON, J. M., ELLIOTT, G. R., GREENHILL, L. L., WIGAL, T., ARNOLD, L. E., VITIELLO, B., HECHTMAN, L., EPSTEIN, J. N., PELHAM, W. E., ABIKOFF, H. B., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180686d7e · Cited by 323 · see citing works
Effect of Stimulants on Height and Weight: A Review of the Literature
Faraone, S. V., Biederman, J., Morley, C. P., & Spencer, T. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.obo13e31817eoea7 · Cited by 286 · see citing works
Self-citationStimulant-Related Reductions of Growth Rates in the PATS
SWANSON, J., GREENHILL, L., WIGAL, T., KOLLINS, S., STEHLI, A., DAVIES, M., CHUANG, S., VITIELLO, B., SKROBALA, A., POSNER, K., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235075.25038.5a · Cited by 264 · see citing works
Self-citationAdler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Self-citationDoes Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?
SPENCER, T. J., FARAONE, S. V., BIEDERMAN, J., LERNER, M., COOPER, K. M., & ZIMMERMAN, B. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000205710.01690.d4 · Cited by 125 · see citing works
Self-citationGrowth of Hyperactive Children Treated With Methylphenidate
Satterfield, J. H. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780020102011 · Cited by 114 · see citing works
Faraone, S. V., Biederman, J., Monuteaux, M. C., & Spencer, T. J. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.191 · Cited by 80 · see citing works
Self-citationSchertz, M., ADESMAN, A. R., Alfieri, N. E., & Bienkowski, R. S. (1996) · PEDIATRICS · doi:10.1542/peds.98.4.763 · Cited by 70 · see citing works
Long-Term Effects of Methylphenidate Transdermal Delivery System Treatment of ADHD on Growth
FARAONE, S. V., & GIEFER, E. E. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31806ad1d7 · Cited by 55 · see citing works
Self-citationDoes extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?
Sund, A. M., & Zeiner, P. (2002) · Nordic Journal of Psychiatry · doi:10.1080/08039480252803936 · Cited by 46 · see citing works
Faraone, S. V. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1565 · Cited by 33 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140 · see citing works
Self-citationCoghill, D. R., Banaschewski, T., Nagy, P., Otero, I. H., Soutullo, C., Yan, B., Caballero, B., & Zuddas, A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0443-y · Cited by 45 · see citing works
Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs · doi:10.2165/11634340-000000000-00000 · Cited by 30 · see citing works
Update on optimal use of lisdexamfetamine in the treatment of ADHD
Madaan, V., Kolli, V., Bestha, D., & Shah, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34092 · Cited by 19 · see citing works
Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD
Dew, R. E., & Kollins, S. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.531009 · Cited by 14 · see citing works
Self-citation
- Authors
- Faraone, S. V., Spencer, T. J., Kollins, S. H., & Glatt, S. J.
- Affiliations
- SUNY Upstate Medical University (US)
- Harvard University (US)
- Duke University (US)
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 49
- Issue
- 1
- Pages
- 24-32
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2013338353
- Cited by
- 39
- References
- 15
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2018: 5 · 2017: 3 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 6
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, growth, height, weight, body mass index, stimulant medication, children, growth monitoring, cumulative drug exposure
- MeSH terms
- Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Body Height, Body Weight, Child, Dextroamphetamine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Body Mass Index, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
